Neuropathy and efficacy of once weekly subcutaneous bortezomib in multiple myeloma and light chain (AL) amyloidosis.

While our SC twice a week BTZ group was too small to draw conclusions, our data compare favorably to a reported PN incidence of 38% for twice weekly SC BTZ administration.[ 17 ] Although there was a trend of increased neuropathy in the presence of conditions known to cause neuropathy like diabetes, it did not reach statistical significance.

also in 111,027 other papers